The future of anti-CD20 monoclonal antibodies: are we making progress?
about
Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodiesApproaches to improve tumor accumulation and interactions between monoclonal antibodies and immune cellsMonoclonal antibodies for the treatment of cancerNovel CD20 monoclonal antibodies for lymphoma therapyAntibody effector functions mediated by Fcγ-receptors are compromised during persistent viral infection.Exosomes released by chronic lymphocytic leukemia cells induce the transition of stromal cells into cancer-associated fibroblastsAssociation between polymorphism of CD20 gene and chronic lymphocytic leukemia in Chinese population.Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patientsAssociation of rituximab with graphene oxide confers direct cytotoxicity for CD20-positive lymphoma cellsReactive oxygen species induced by therapeutic CD20 antibodies inhibit natural killer cell-mediated antibody-dependent cellular cytotoxicity against primary CLL cells.Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study.A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies.Recombinant IgE antibodies for passive immunotherapy of solid tumours: from concept towards clinical application.Mechanisms of action of CD20 antibodies.Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia.B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies.Safety and efficacy of ofatumumab in patients with fludarabine and alemtuzumab refractory chronic lymphocytic leukaemia.Higher World Health Organization grades of follicular lymphoma correlate with better outcome in two Nordic Lymphoma Group trials of rituximab without chemotherapy.Accelerated therapeutic progress in diffuse large B cell lymphoma.Monoclonal antibodies as therapeutics in human malignancies.Update on obinutuzumab in the treatment of B-cell malignancies.Emerging drugs for diffuse large B-cell lymphoma.Biosimilar monoclonal antibodies in lymphoma: a critical appraisal.Natural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactions.Humanization of chimeric anti-CD20 antibody by logical and bioinformatics approach with retention of biological activity.Potential of glycosylation research in graft versus host disease after allogeneic hematopoietic stem cell transplantation.Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia: from uncertainties to promises.Obinutuzumab: A Review in Rituximab-Refractory or -Relapsed Follicular Lymphoma.Development of Novel Anti-Cd20 Monoclonal Antibodies and Modulation in Cd20 Levels on Cell Surface: Looking to Improve Immunotherapy ResponseEnhancement of Rituximab-induced cell death by the physical association of CD20 with CD40 molecules on the cell surface.Atomic force microscopy study of the antigen-antibody binding force on patient cancer cells based on ROR1 fluorescence recognition.Diagnosis and treatment of CD20 negative B cell lymphomas.Regulation of drug-metabolizing enzymes in infectious and inflammatory disease: implications for biologics-small molecule drug interactions.Rituximab for the treatment of follicular lymphoma.Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway.Comparison of different suicide-gene strategies for the safety improvement of genetically manipulated T cells.Characterization of the B cell response to Leishmania infection after anti-CD20 B cell depletion.Antibody-dependent fragmentation is a newly identified mechanism of cell killing in vivo.A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cellsBiosimilar, biobetter and next generation therapeutic antibodies
P2860
Q21131216-30D6B02F-BDB4-473A-862E-4A48228E1AE1Q26852287-9E17C190-E8BE-427A-9AEB-B63B4321366BQ27025966-3724762C-FC5F-49F0-823D-5CA64F8B4DCDQ28390112-00FEC761-1A85-43AE-B2C4-8C5D35E6C887Q35116554-C319077D-02B9-4700-ACB6-402A9A7C483BQ36028740-647DBD5B-A72B-4703-957E-A603FFF8A7DFQ36046580-E56BFE03-3264-44B3-8C26-059085DA646FQ36806268-45DFA0E2-85A8-4CDC-899E-5C6215031C05Q37022297-EF6340C4-649F-4817-978B-7E38ED70ACA6Q37362596-CCBE6122-622B-4023-B18B-135F7696F09FQ37380415-D638C5A7-A650-4DA0-B037-41953099472BQ37672472-276B9B88-1EE5-4909-BD07-4F875C4FA2A8Q37964490-EDA4A513-5840-4767-A28B-DAA02D6405CDQ38066195-8FE2BCF0-8EDF-4394-BEAD-882F965EA1D5Q38068932-FD9A92E8-1D41-4BA2-B511-C967149CA26DQ38097170-1076C243-8764-41AA-A97D-E524687234EAQ38100787-F4FE29EA-08EA-4258-BD72-7B6780B24E0CQ38105625-ABDE3061-827B-46FE-9F9E-9DC53C878C64Q38174498-1DE85311-3ED4-4E92-8E55-8B596D8E5455Q38206275-8757D1AF-7DC0-4F23-A1FC-AE7FABF758A8Q38246230-AE3B1E4E-DA00-4C6B-91E1-04EA92F25EADQ38344404-EF56B38B-C1F7-404E-A909-59478E775A9AQ38394272-B3139424-39F3-4C5D-B4D5-007327D04F87Q38542034-FC894411-5CD8-4C9F-A800-706F18A6A27BQ38735872-4134A358-E847-47CA-8693-6D7FC2F24158Q38753771-9AF6B457-9E2A-4038-B66C-DABB3A8A9B82Q38824182-73102E7B-E9E3-4878-9E4D-B557B93470C9Q38889978-DBF055E9-8B8F-4A86-B9BE-674726B5BC93Q38896113-17E75FEB-6E71-486E-A4AF-138AD1C1D52CQ38988648-C578BA78-4C7F-4225-8E0F-4929925FDD74Q39128700-7D64BD08-9DFD-4810-9567-AD6461A8B18EQ39132786-79BCDC55-9986-4E4A-80E4-87218B353193Q39325953-009ED9BC-A8DC-4072-937E-77CAD460C70CQ39360775-910DC42E-A400-4BC6-91B2-D25DB1DD6A2DQ39392738-198527F7-6D7A-40F1-A710-B674655BF44DQ39408105-8C3B8481-A101-44BD-810D-57F91DE80ED0Q41059758-823A49DE-3E32-402D-AA80-56A0CDA81011Q41620299-49DC9902-F7FF-4D96-AD39-BC7A94E14D8BQ42601428-6351A187-6C48-46A0-A75B-A56D1B5A992DQ42732007-D23AD3A9-651C-41BC-AED3-4F1B302D33A7
P2860
The future of anti-CD20 monoclonal antibodies: are we making progress?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 05 January 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The future of anti-CD20 monoclonal antibodies: are we making progress?
@en
The future of anti-CD20 monoclonal antibodies: are we making progress?
@nl
type
label
The future of anti-CD20 monoclonal antibodies: are we making progress?
@en
The future of anti-CD20 monoclonal antibodies: are we making progress?
@nl
prefLabel
The future of anti-CD20 monoclonal antibodies: are we making progress?
@en
The future of anti-CD20 monoclonal antibodies: are we making progress?
@nl
P1433
P1476
The future of anti-CD20 monoclonal antibodies: are we making progress?
@en
P2093
Waleed Alduaij
P304
P356
10.1182/BLOOD-2010-07-298356
P407
P577
2011-01-05T00:00:00Z